OTCM
NNCSF
Market cap636mUSD
, Last price
Name
Nanosonics Ltd
Chart & performance
P/E
—
P/S
—
EPS
0.06
Vol. 1Y
—
Shs. 5Y
0.24%
Rev. 5Y
14.85%
Div Yld LY
—
Div Yld TTM
—
Revenues
203m
+2.28%
Net income
18m
-13.74%
CFO
23m
-48.73%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
Key people
Independent Non-Executive Chairman of the Board · since 2022
Michael Kavanagh
President, Chief Executive Officer, Managing Director, Executive Director · since 2013
Jason Burriss
Chief Financial Officer · since 2023
William Haydon
Regional President, North America · since 2025
Ken Shaw
Regional President for the United States, Canada and Latin America · since 2024
Ronan Wright
Regional President for Europe, Middle East and Africa · since 2019
Rod Lopez
Chief Operating Officer · since 2019
Jodi Sampson
Chief People and Culture Officer · since 2020
Derek Minihane
Chief Technology Officer · since 2025
Sunny Pillai
Chief Information Officer · since 2022
Kimberly Hill
Chief Marketing Officer · since 2025
Matthew Lipscombe
Chief Marketing Officer · since 2022
Jonathan Burdach
Chief Medical Affairs and Scientific Officer · since 2024
Matthew Carbines
General Counsel, Company Secretary · since 2023
Non-Executive Director · since 2023
Larry Marshall
Non-Executive Director · since 2023
Non-Executive Independent Director · since 2026
Non-Executive Independent Director · since 2025
Marie Elizabeth Mcdonald
Non-Executive Independent Director · since 2023
Lisa McIntyre
Independent Non-Executive Director · since 2019
Headquarters & legal address
Level 1, Building A, 7-11 Talavera Road
Macquarie Park
Sydney, NSW 2113
AU
Macquarie Park
Sydney, NSW 2113
AU
Previous name
NANOSONICS PTY LTD
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||